Research programme: cardiovascular and metabolic disease therapeutics - Genfit/Pierre Fabre

Drug Profile

Research programme: cardiovascular and metabolic disease therapeutics - Genfit/Pierre Fabre

Latest Information Update: 09 Jan 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Genfit; Pierre Fabre
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Cardiovascular disorders; Lipid metabolism disorders; Metabolic disorders

Most Recent Events

  • 07 Jan 2008 Genfit and Pierre Fabre renew their research alliance for cardiometabolic disease therapies
  • 07 Jan 2008 Preclinical trials in Metabolic disorders in France (unspecified route)
  • 01 May 2006 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top